CET (GMT + 1 / UTC + 1)
To convert the congress times to your local time Click Here
The viewing of session cannot be accessed from this conference calendar. All sessions are accessible via the Main Lobby at the Virtual Platform.
This session will focus on three key topics:
What is the role of viral replication in COVID-19 and the impact of preventing it?
When and how should remdesivir treatment be initiated based on the clinical trials evidence?
What are the learnings from using remdesivir in clinical practice?
This is a promotional meeting organised and funded by Gilead Sciences Europe Ltd. and will include materials and discussions of Veklury®(remdesivir). This medicinal product is currently subject to additional monitoring, as indicated by the presence of the inverted black triangle. Any suspected adverse reactions to Veklury® (remdesivir) should be reported to Gilead safety and to your national reporting system Full prescribing information for Veklury and adverse event reporting instructions can be accessed here: https://www.medicines.org.uk/emc/product/11597/smpc IHQ-COVID-19-2021-02-0012; February 2021